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Abstract
Increasing evidence indicates that microRNAs (miRNAs) are contributing factors to neuro-
degeneration. Alterations in miRNA signatures have been reported in several neurodegen-
erative dementias, but data in prion diseases are restricted to ex vivo and animal models.
The present study identified significant miRNA expression pattern alterations in the frontal
cortex and cerebellum of sporadic Creutzfeldt-Jakob disease (sCJD) patients. These
changes display a highly regional and disease subtype-dependent regulation that correlates
with brain pathology. We demonstrate that selected miRNAs are enriched in sCJD isolated
Argonaute(Ago)-binding complexes in disease, indicating their incorporation into RNA-
induced silencing complexes, and further suggesting their contribution to disease-associ-
ated gene expression changes. Alterations in the miRNA-mRNA regulatory machinery and
perturbed levels of miRNA biogenesis key components in sCJD brain samples reported
here further implicate miRNAs in sCJD gene expression (de)regulation. We also show that a
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subset of sCJD-altered miRNAs are commonly changed in Alzheimer’s disease, dementia
with Lewy bodies and fatal familial insomnia, suggesting potential common mechanisms
underlying these neurodegenerative processes. Additionally, we report no correlation
between brain and cerebrospinal fluid (CSF) miRNA-profiles in sCJD, indicating that CSF-
miRNA profiles do not faithfully mirror miRNA alterations detected in brain tissue of human
prion diseases. Finally, utilizing a sCJD MM1 mouse model, we analyzed the miRNA dereg-
ulation patterns observed in sCJD in a temporal manner. While fourteen sCJD-related miR-
NAs were validated at clinical stages, only two of those were changed at early symptomatic
phase, suggesting that the miRNAs altered in sCJD may contribute to later pathogenic pro-
cesses. Altogether, the present work identifies alterations in the miRNA network, biogenesis
and miRNA-mRNA silencing machinery in sCJD, whereby contributions to disease mecha-
nisms deserve further investigation.
Author summary
miRNAs are small non-coding RNAs that regulate gene expression through complemen-
tary binding to their mRNA targets. Specific miRNA signatures have been proposed for
several neurodegenerative diseases supporting the idea that miRNA deregulation is a com-
mon disease hallmark. Here we present the comprehensive miRNA signature in sporadic
Creutzfeldt-Jakob disease (sCJD). Our study unravels the complex network of regional
and disease-subtype miRNA alterations, and the presence of a disturbed miRNA biogene-
sis pathway and miRNA-mRNA silencing machinery. We also highlight the existence of
time-dependent miRNA profiles and identify commonly regulated miRNAs between sev-
eral dementias with cortical pathology sharing a partial clinical overlap and pathological
involvement with sCJD. The present data shed light on the potential role of miRNAs as a
contributing factor of pathogenic molecular traits associated with sCJD.
Introduction
Creutzfeldt-Jakob disease (CJD) is a human transmissible spongiform encephalopathy charac-
terized by behavior changes, progressive dementia, loss of coordination and myoclonus. At the
molecular level, CJD is associated with the conversion of the normal, cellular prion protein
(PrPC) to an abnormal conformation (PrPSc) and further accumulation of PrPSc in the brain
in the form of protein aggregates [1]. Despite the established role of PrPC in several neuronal
functions such as synaptic plasticity, neurotransmission and neuronal development, the
molecular mechanisms triggering the PrPC to PrPSc conversion and the cellular pathways
unchained by prion infection leading to neuronal damage and cell death remain elusive.
Sporadic CJD (sCJD) is the most common human prion disease, presenting a high degree
of heterogeneity. sCJD is classified into six subtypes, based on variations at codon 129 of the
prion protein gene (PRNP Met or Val) and on the size of protease resistant PrPSc (type 1 or 2).
Among these subtypes MM1 and VV2 are the most prevalent [2,3] and give rise to unique clin-
ical and neuropathological features, such as specific gliosis, neuroinflammation, spongiosis
and synaptic loss signatures [2,4–7]. A widespread regional and subtype-specific mRNA and
protein deregulation leading to the alteration of multiple biological functions and signaling
pathways is also associated with sCJD [5,8–10].
microRNAs in Creutzfeldt-Jakob disease
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Transcriptomic and proteomic patterns are regulated by several factors including miRNAs;
these have been recognized as key regulators of gene expression. miRNAs are small (21–25
nucleotides long), non-coding RNAs, that regulate gene expression through partial comple-
mentary binding to their mRNA targets in the RNA-induced silencing complex (RISC). This
miRNA-mRNA interaction usually leads to gene silencing through a variety of forms, includ-
ing mRNA cleavage, translational repression and de-adenylation [11,12].
Several miRNAs are selectively expressed in the central nervous system (CNS) and have
been reported to be involved in CNS development, function and pathogenesis [13,14]. In addi-
tion, specific miRNA signatures have been proposed for Alzheimer’s (AD), Parkinson’s (PD)
and Huntington’s (HD) disease, as well as for Fronto-temporal dementia (FTD) [15–20], sup-
porting the idea that miRNA deregulation is a common hallmark of neurodegenerative dis-
eases. While the study of miRNAs in relation to prion pathogenesis has gained experimental
momentum since several miRNAs were found to be altered in in vivo and ex vivo models of
prion diseases [21–25], the miRNA signature in sCJD has not been reported so far.
A potential link between miRNAs and prion diseases has been suggested based on the co-
localization of PrPC within RISC components in endosomes and multivesicular bodies. Bind-
ing of PrPC to the type III RNase Dicer (Dicer) and Argonaute (Ago) proteins, which repre-
sent essential components of the RISC loading complex, has been proposed as a requirement
for effective repression of several miRNA targets [26]. Hence, miRNA deregulation could be
triggered by many aspects of sCJD pathology, including replacement of the physiological PrP
forms with pathological ones. Simultaneously, miRNA deregulation may have drastic conse-
quences in sCJD gene expression patterns and may act as a contributing factor in the cascade
of events leading to fast disease progression.
In order to increase our understanding of the miRNA contribution to sCJD pathogenesis,
we performed small RNA-Sequencing (small RNA-Seq) in the two most affected brain regions
in sCJD, frontal cortex (FC) and cerebellum (CB), in the two most prevalent sCJD subtypes
(MM1 and VV2), which are linked to region specific clinical and pathological outcomes [2,27].
We demonstrate a strong regional and subtype-specific alteration of miRNA expression in
sCJD and molecular alterations in miRNA biogenesis and silencing machinery; we further
show that a subset of sCJD enriched miRNAs are actively incorporated in the RISC complex.
Additionally, we detected the presence of commonly changed miRNAs in other neurodegener-
ative dementias such as AD, dementia with Lewy bodies (DLB) and fatal familial insomnia
(FFI). Further, sCJD-related miRNA alterations were studied in a temporal manner, utilizing a
sCJD mouse model; sCJD miRNA profiles were validated in the utilized animal model at clini-
cal disease stages, whereas most of those miRNAs were not found to be regulated at earlier dis-
ease points suggesting diverse and dynamic miRNA expression programs during disease
progression. Finally, we profiled selected miRNAs in the CSF of sCJD cases, which ruled out
the presence of a major correlation between miRNA levels in CSF and brain tissue.
Altogether, our results show a significant deregulation of miRNA expression, activity and
biogenesis in sCJD and they highlight the potential role of miRNAs in the pathology of prion
diseases and alternative neurodegenerative conditions.
Results
Altered miRNA signatures in the FC and CB of sCJD MM1 and VV2 cases
miRNA expression signatures were determined by small RNA sequencing in the frontal cortex
(FC) and in the cerebellum (CB) of sCJD MM1 and VV2 and in age and gender matched con-
trols. We selected these brain regions, because they are strongly affected in sCJD and display
differential neuropathological patterns between MM1 and VV2 subtypes [2, 27]. Obtained
microRNAs in Creutzfeldt-Jakob disease
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sequences were annotated based on the overlap with publicly available genome annotations,
including miRNAs, tRNAs, rRNAs, other small RNAs and genomic repeats. miRNAs repre-
sented an average of 27% of total counts (S1 Table). Total number of reads on the FC and CB
mapping onto miRNAs with at least 2 counts in a given sample are shown (S2 Table). Two
independent pipelines were used for the analysis of the differential miRNA expression, Seqbus-
ter [28] and OASIS [29]. Both pipelines showed a high level of agreement in the detection of
differentially expressed miRNAs (89%). Seqbuster analysis revealed the presence of 70 miR-
NAs with altered expression in the FC of sCJD MM1 and 27 in sCJD VV2 compared to con-
trols (Fig 1A, S3 Table). In the CB, 22 miRNAs were changed in sCJD MM1 and 69 in sCJD
VV2 compared to controls (Fig 1A, S3 Table). The majority of the differentially altered miR-
NAs were expressed in both tissues, suggesting that the changes on their levels are tissue spe-
cific (S2 and S3 Tables).
The miRNA signature in sCJD was highly dependent on the brain region and sCJD subtype
(Fig 1B and S3 Table). Regarding sCJD subtype alterations, a high percentage of miRNAs were
commonly regulated between both subtypes in the FC (31%) (Fig 1B). In the CB, the percent-
age of commonly altered miRNAs between subtypes was lower (10%) (Fig 1B).
miRNA variability is ubiquitous in the brain of control and sCJD cases
Isoforms of a mature miRNA have been referred as isomiRs [30]. They are functionally active
and highly abundant in brain tissue, both in control and in neurodegenerative diseases
[15,31,32]. In the present study, 2883 and 4075 different isomiRs were found in the CB and
FC, respectively (S4 Table). Furthermore, most of the sequences mapping onto miRNA data-
base (reference miRNAs and IsomiRs) showed 3–50 counts. No major differences were
detected between control and sCJD subtype cases regarding their isomiRs profiles (S2 Fig),
suggesting that isomiR processing is not significantly altered in sCJD.
sCJD-related miRNA validation and enrichment in RISC complexes
A subset of miRNAs found to display altered expression in sCJD based on small RNA-Seq
analysis was further validated by qPCR analysis. miRNAs were selected according to number
of counts and fold change alterations in the RNA-seq analysis and/or their previous association
with prion disease pathogenesis and/or other neurodegenerative diseases [21,23,33,34]. A total
of 18 miRNAs were analyzed in both regions. The alterations in the levels of 15 and 10 miR-
NAs were validated in a regional specific manner in the FC and CB, respectively (Fig 2A). In
sCJD FC, miRNAs 29b-3p, 342-3p, 146a-5p, 154-5p, 195-5p, 26a-5p, 16-5p, 449a, 142-3p,
let7i-5p and 135a-5p were increased, while miRNAs 124-3p, 331-3p, 877-5p and 125a-5p were
decreased compared to controls, in agreement with RNA-seq data. miRNAs 378a-3p and
5701, which expression was only altered in CB did not present changes in the FC. In CB, miR-
NAs 146a-5p, 154-5p, 26a-5p, 378a-3p, 449a, 142-3p, let7i-3p and 5701 were increased, and
miRNAs 124-3p and 877-5p were decreased in sCJD, in agreement with RNA-seq data. The
rest of miRNAs, which expression was only altered in FC did not present changes in the CB.
Finally, miRNA-204-5p, a miRNA presenting no alterations in the FC and CB of sCJD by
RNA-seq analysis, was used as negative control showing no changes among groups at qPCR
level. Therefore, while most of the qPCR validated miRNAs were altered in both disease sub-
types, a subset of them presented subtype-specific changes, which were in agreement with
small RNA-Seq data (S3 Table).
To confirm that upregulated miRNAs in sCJD brain tissue were functionally active, we
performed RISC immunoprecipitations in the FC of control and sCJD MM1 cases using two
different Argonaute (Ago) antibodies detecting Ago-2 (11A9) and Ago1-4 family members
microRNAs in Creutzfeldt-Jakob disease
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Fig 1. Small RNA-Seq analysis and miRNA expression levels in the FC and CB of sCJD. (A) Relative quantitation of
regulated miRNAs in the FC and CB of sCJD MM1 and VV2 subtypes compared to age and gender matched controls
microRNAs in Creutzfeldt-Jakob disease
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(H-300). These antibodies were able to immunoprecipitate Ago-containing miRNA complexes
from brain tissue (Fig 2B). RNA extraction from immunoprecipitates and further qPCR
by small RNA-Seq. For FC 13 controls, 11 sCJD MM1 and 13 sCJD VV2 were analyzed. For CB: 12 controls, 12 sCJD
MM1 and 9 sCJD VV2 were analyzed. Differential expression in miRNA sequencing data was evaluated with the
DESeq2 tool and significantly differently expressed miRNAs were detected according to an adjusted p value of<0.05.
Data represent log2 fold change for each comparison. log2 fold change was>0.5 for upregulated miRNAs and<-0.5
for downregulated miRNAs. MA plots are also supplied for data visualization (S1 Fig). (B) Venn diagram of subtype-
dependent altered miRNA in the FC and CB of sCJD by small RNA-Seq. Percentage of maximal coincidence
(percentage of maximal number of miRNAs that can be coincident between groups) is indicated.
https://doi.org/10.1371/journal.ppat.1006802.g001
Fig 2. Regional and subtype-dependent miRNA expression confirmation and representative miRNA incorporation into functional complexes. (A)
Validation of the small RNA-Seq signature in selected miRNAs by RT-qPCR analysis in the FC (upper panel) and CB (lower panel) of controls, sCJD MM1
and VV2. Results were normalized to the housekeeping genes U6 snRNA (figure) and RNU5 expression, which showed similar results in the expression
analysis of deregulated miRNAs between control and sCJD cases. Housekeeping gene levels remained unaltered between groups. Normalization was
performed relative to controls. Error bars indicate SD. (B) Detection of sCJD-related miRNAs by RT-qPCR in Ago immunoprecipitates from the FC of
controls (n = 3) and sCJD MM1 brain homogenates (n = 3). The two Ago antibodies used (11A9 and H-300) were able to immunoprecipitate Ago-2 from
brain tissue (left panel) and reported similar results in the specific enrichment of sCJD-related miRNAs (146a-5p, 26a-5p, 195-5p, 154-5p, 204-5p and 5701)
in the FC of sCJD MM1 cases (right panels). miRNA-204-5p was selected as negative control, since no changes were detected between control and sCJD
cases with small RNA-Seq and RT-qPCR analysis. Non-specific immunoglobulins (NS) were used as control antibody for the immunoprecipitation. Error
bars indicate SD. (C) Upper panel: western blot analysis of Ago-2 (11A9 antibody) in the FC and CB control, sCJD MM1 and VV2 cases. Four
representative cases per diagnostic group and brain region are shown in the western blot. Quantifications derived from densitometry analysis were
performed in 15 cases per diagnostic group (n = 15/group). β-actin was used as loading control. Densitometries of the western blots are shown.
Normalization was performed relative to controls. Error bars indicate SD. Bottom panel: Gene expression levels of Ago-2 in the FC and CB of controls,
sCJD MM1 and VV2 cases by RT-qPCR. Results were normalized to housekeeping genes GAPDH (figure) and GUSB with similar results. Housekeeping
levels remained unaltered between groups. 10 cases per diagnostic group (n = 10/group) were analyzed. In all cases, statistical significance (compared to
controls) was set at p<0.05.
https://doi.org/10.1371/journal.ppat.1006802.g002
microRNAs in Creutzfeldt-Jakob disease
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006802 January 22, 2018 6 / 33
analysis allowed us to detect miRNA enrichment for a subset of miRNAs with increased
expression in sCJD MM1 brain tissue according to qPCR analysis (miRNA-146a-5p, miRNA-
26a-5p, miRNA-195-5p and miRNA-154-5p). As negative controls, miRNA-204-5p and
miRNA-5701 were tested. According to RNA-seq and qPCR data, miRNA-204-5p was regu-
lated neither in the FC nor in the CB of sCJD, while miRNA-5701 was upregulated only in the
CB of sCJD cases. In agreement with this, miRNA-204-5p and miRNA-5701 levels were
unchanged in RISC immunoprecipitates between control and sCJD cases (Fig 2B). To rule out
the possibility that the differences in RISC-miRNA enrichment were due to alterations in Ago-
2 expression between controls and sCJD, Ago-2 levels were analyzed by qPCR and western
blot. No alterations were found in Ago-2 protein and mRNA levels between controls and sCJD
cases, either in the FC or in the CB (Fig 2C). Similarly, no changes on the expression levels of
GW182, an Ago binding protein essential for miRNA-mediated gene silencing [35] were
detected between control and sCJD cases (S3A and S3B Fig).
Alterations in miRNA-mRNA silencing complexes in sCJD
Next, we investigated potential alterations in the miRNA-mRNA silencing complexes that
could explain the alterations in sCJD miRNA signatures previously detected. As a first step, we
performed gel filtration chromatographic assays of control and sCJD brain homogenates. Ten
fractions containing different proteomic patterns according to their molecular weight were
obtained. PrP levels were homogeneously distributed along the chromatographic fractions as
described before [36,37] (S4A and S4B Fig). Western blot analysis revealed the presence of
Ago-2 in higher molecular weight fractions in sCJD compared to control samples, suggesting
that Ago-2 in sCJD is interacting with a different subset of partners (Fig 3A). This is in agree-
ment with a different subcellular localization of Ago in sCJD brain tissue as revealed by immu-
nohistochemistry analysis. Indeed, using two different antibodies, we detected an increased
nuclear localization of Ago in the FC of sCJD MM1 and VV2 cases, in contrast to controls,
where staining was mainly detected in the cytoplasmic compartment (Fig 3B and S5A and S5B
Fig). While Ago-2 expression was mainly detected in neurons, both in controls and sCJD
cases, double immunofluorescence analysis revealed the presence of Ago-2 positive microglial
cells (S5 Fig). In contrast, no differences on subcellular localization were detected for GW182
between control and sCJD cases (S3 Fig).
PrP and Ago-2 are interacting proteins in physiological conditions [26], but nothing is
known about the potential role of PrPSc in the RISC complex. Since the endosomal compart-
ment, in which RISC assembly and turnover occurs, has been proposed as a site of prion con-
version [38] we aimed to investigate the presence of PrPSc in Ago-2 complexes, which could
be one of the contributors to their altered chromatographic Ago-2 patterns in sCJD. To this
end, Ago-2 immunoprecipitates from the FC of controls and sCJD MM1 were subjected to
RT-QuIC analysis. Positive signal was detected in immunoprecipitates from sCJD samples,
but not from controls (Fig 3C), indicating the presence of pathogenic PrP in Ago-2 complexes,
in agreement with the presence of RT-QuIC signal and protein oligomers in Ago-2 containing
chromatographic fractions (S4C and S4D Fig).
The alteration of RISC components in sCJD and the well-known presence of reticulum
stress in models of prion disease [39–41] raised the possibility that stress granules (SG), which
are normally transient structures, form stable complexes in sCJD. Immunohistochemical and
immunoblot analysis of the SG markers eukaryotic initiation factor 3 (eIF3) and T-cell-
restricted intracellular antigen-1 (Tia-1) revealed that, in sCJD, neither their subcellular locali-
zation nor their expression levels were altered (Fig 3D and 3E). In agreement with this, we did
not detect hyper-phosphorylation of the SG activator eIF2α in sCJD (Fig 3D). Similarly, levels
microRNAs in Creutzfeldt-Jakob disease
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Fig 3. Alterations in the levels and distribution of the miRNA silencing machinery in sCJD. (A) Western blot analysis for Ago-2
immunodetection (upper panel) and densitometry (lower panel) of the chromatography gel filtration fractions from the FC of control (n = 3)
and sCJD MM1 (n = 3) cases. Western blot analysis shows a representative image of a control and a sCJD case, while densitometry shows
microRNAs in Creutzfeldt-Jakob disease
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of the SG and p-bodies marker DEAD-Box Helicase 6 (p54/rck) showed no alterations
between controls and sCJD. However, increased expression levels of the specific p-bodies
marker decapping mRNA 1a (dcp1a) was detected in sCJD MM1 and VV2 (Fig 3E). Alto-
gether, our findings suggest the presence of alterations in the p-bodies-dependent mRNA
decay mechanisms without the activation of stress granule responses.
Altered miRNA biogenesis machinery in sCJD
Disruption of the miRNA biogenesis pathway components might cause alteration of miRNA
homeostasis and neurodegeneration [42,43]. miRNA alterations in sCJD prompted us to con-
sider possible alterations in the miRNA biogenesis pathway. The expression levels of three key
components of miRNA biogenesis, the ribonucleases Dicer and Drosha and the microproces-
sor complex DGCR8, a cofactor of Drosha, were studied in sCJD brain samples. mRNA
expression analysis revealed decreased DGCR8 levels in the CB of sCJD cases (Fig 4A). At the
protein level, Drosha levels were significantly lower in the FC of sCJD MM1 and in the CB of
sCJD VV2, resembling the regional and subtype pathological involvement of the disease.
Decreased Dicer levels were detected in the FC of sCJD MM1, while reduced levels of DGCR8
were found in the CB of sCJD VV2 (Fig 4B). The absence of direct regional and/or subtype-
specific alterations among the main components of the miRNA biogenesis pathway suggests
the presence of a complex impairment of the miRNA biogenesis machinery in sCJD. Addition-
ally, we investigated the expression levels of Exportin 5, a RanGTP-dependent dsRNA-binding
protein mediating pre-miRNAs nuclear export [44,45], which expression is deregulated in AD,
but not in PD or Down’s syndrome dementia [46]. Exportin 5 levels in sCJD were altered nei-
ther at mRNA nor at protein levels compared to controls (S6 Fig).
Neural-type miRNA expression profiling in sCJD
A prominent hallmark in sCJD pathogenesis is the concomitant increase of neuronal loss and
gliosis [2,47]. Since cell-type specific miRNA signatures have been described in neural popula-
tions [34,48,49], we aimed to investigate the neural-type miRNA expression profiling in sCJD.
First, sCJD-regulated miRNAs were compared to those reported to be enriched in neurons,
microglia and astrocytes [34]. The expression of neuron-enriched miRNAs was not signifi-
cantly altered in sCJD (Fig 5A), indicating that the sCJD-related miRNA signature is not a
mere consequence of neuronal death. On the other hand, most microglia and astrocyte-
enriched miRNAs presented deregulated levels in sCJD, most likely as a result of glial prolifera-
tion and activation. To gain insight into subcellular and neural-type localization of sCJD-asso-
ciated miRNAs in human brain tissue, in situ hybridizations were performed for the following
miRNAs: miRNA-124-3p, miRNA-26-5p and miRNA-146a-5p (Fig 5B and 5C). The three
miRNAs were localized in the cytoplasm of neurons. Additionally, miRNA-146a-5p labeling
was also detected in capillary walls and in some small cells compatible with glial morphology.
mean values and SD of all cases studied. (B) Representative fluorescence photomicrographs of Ago immunoreactivity in the FC of control
and sCJD MM1 cases. The two antibodies used (11A9 and H-300) showed similar Ago distribution between control and sCJD MM1 cases.
Scale bar = 25μm (C) RT-QuIC analysis of Ago-2 immunoprecipitates (11A9) obtained from the FC of brain homogenates of control (n = 3)
and sCJD MM1 (n = 3) cases. RT-QuIC assays were run in triplicate for each sample. A representative curve for each condition is shown. (D)
Representative fluorescence photomicrographs of eIF3, Tia-1 and p-eIF2α(Ser51) immunoreactivity in the FC of control and sCJD MM1
cases. Scale bar for eIF3 = 10 μm and Tia-1 = 20μm, for p-eIF2α(Ser51) = 10μm (E) Western blot analysis of eIF3, Tia-1, p54/rck and dcp1a in
the FC of control, sCJD MM1 and VV2 cases. Three representative cases per diagnostic group and brain region are shown in the western
blot. Quantifications derived from densitometry analysis were performed in 15 cases per diagnostic group (n = 15/group). GAPDH was used
as a loading control. Densitometries of the western blots are shown. Normalization was performed relative to controls. Error bars indicate
SD. In all cases, statistical significance (compared to controls) was set at p<0.05.
https://doi.org/10.1371/journal.ppat.1006802.g003
microRNAs in Creutzfeldt-Jakob disease
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Fig 4. Altered expression levels of miRNA biogenesis components in sCJD. (A) Gene expression levels of Drosha (n = 10),
DGCR8 (n = 10) and Dicer (n = 10) in the FC and CB of controls, sCJD MM1 and VV2 cases by RT-qPCR. Results were
normalized to housekeeping genes GAPDH (figure) and GUSB with similar results. Housekeeping levels remained unaltered
between groups. (B) Protein levels of Drosha, DGCR8, Dicer in the FC and CB of controls, sCJD MM1 and VV2 cases, by
western blot analysis. Three representative cases per diagnostic group and brain region are shown in the western blot.
Quantifications derived from densitometry analysis were performed in 15 cases per diagnostic group (n = 15/group). β-actin
was used as a loading control. Densitometries of the western blots are shown. Normalization was performed relative to controls.
Error bars indicate SD. In all cases, statistical significance (compared to controls) was set at p<0.05.
https://doi.org/10.1371/journal.ppat.1006802.g004
microRNAs in Creutzfeldt-Jakob disease
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Fig 5. Neural-type miRNA profiling in sCJD. (A) Heat map analysis of the neuron, microglia and astrocyte enriched miRNAs, whose levels
were changed in the FC and CB of sCJD MM1 and VV2 cases by RNA-seq analysis. Neural-type enriched miRNAs were reported in the
bibliography based on neural-type enrichment analysis (49). (B) In situ hybridization of miRNA-124-3p in the FC and CB of control and
sCJD MM1 brain tissue, and of miRNAs 26a-5p and 146a-5p in the FC of sCJD MM1 brain tissue. (C) Quantification of miRNA-124-3p
intensity in the FC and CB of control and sCJD MM1 neurons.>100 neurons in total were quantified for each group. Normalization was
performed relative to controls. AU/neuron indicates arbitrary units quantified in the densitometry analysis for each neuron. Error bars
indicate SD. Scale bar in FC = 30μm and in CB = 50μm. In all cases, statistical significance (compared to controls) was set at p<0.05.
https://doi.org/10.1371/journal.ppat.1006802.g005
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Decreased miRNA-124-3p staining detectable in sCJD was associated with a reduced number
of neurons. However, we also detected less signal intensity in surviving sCJD neurons, both in
the FC and in the CB (Purkinje and granular cells) regions (Fig 5B and 5C), in agreement with
the idea that lower expression of neuronal-related miRNAs in sCJD is not exclusively associ-
ated with neuronal loss.
Cross-validation of sCJD-miRNA signature in alternative
neurodegenerative diseases
Several neurodegenerative disorders share pathological hallmarks such as accumulation of
protein aggregates and self-propagation, and common pathways seem to contribute to the
neurodegenerative mechanisms in different diseases [50–52]. Thus, we speculated that an
overlap between miRNA sCJD profiling and other dementia-related conditions could exist. In
order to select the most appropriate miRNAs we compared the miRNA signatures in the FC of
sCJD obtained from the small RNA-seq analysis from this study with the one reported in the
pre-frontal cortex (PFC) of AD cases by Lau et al. [20]. Eight (22.8% max. coincidence) and
seven miRNAs (14% max. coincidence) were commonly increased and decreased respectively
in both datasets (Fig 6A). Among these, miRNA-195-5p, 877-5p and 323a-5p were previously
validated in sCJD from our small RNA-Seq dataset and miRNA-195-5p and 877-5p were vali-
dated by qPCR (Fig 2A).
To perform a cross-validation study with the corresponding sCJD brain regions and meth-
odologies we extracted RNA from the FC of AD and DLB cases and age-matched controls. Six
miRNAs were selected: i) miRNA-195-5p, 877-5p and 323a-5p, commonly regulated in the FC
of sCJD and in the PFC of AD, ii) miRNA-146a-5p and miRNA-342-3p, reported to be altered
in AD and prion disease models [22,23,53,54] and iii) miRNA-5701. The latter was used as a
negative control due to its exclusive enrichment in the CB of sCJD. In AD samples, we
detected coincident gene expression regulations with sCJD for miRNA-195-5p (increased) and
for miRNA-877-5p and 323a-5p (decreased) (Fig 6B). Rapid progressive forms of AD (rpAD)
mimicking the disease progression and cognitive decline of sCJD [55,56] were included in our
study. No significant differences in the expression levels of the six analyzed miRNAs were
detected between AD and rpAD (Fig 6B). In DLB, we detected coincident gene expression reg-
ulations with sCJD for miRNA-877-5p and miRNA-323a-5p (both with decreased expression
levels) (Fig 6C).
Finally, we extended our analysis to cases of fatal familial insomnia (FFI), a genetic prion
disease presenting mild cortical and cerebellar affection [57,58]. A subset of four sCJD-regu-
lated miRNAs in the FC and CB were tested. Only miRNA-195-5p showed common expres-
sion profiles in sCJD and FFI, with increased expression in both brain regions compared to
age-matched control (Fig 6D) indicating a lack of complete specificity of miRNA patterns
between neurodegenerative diseases from same etiology.
Temporal dependent sCJD miRNA profiling
To gain insights into the temporal-dependent sCJD miRNA profiles we took advantage of the
sCJD MM1 mouse model tg340-PRNP129MM (tg340) inoculated with sCJD MM1 brain
homogenate. Mice were sacrificed at pre-clinical (120 dpi), early clinical (160 dpi) and clinical
(180 dpi and 210 dpi) disease stages. Survival time was 199 ± 7.5 days (Fig 7A). To confirm the
disease-specific regional and subtype neuropathological and biochemical alterations in the
tg340 mice, several prion hallmarks were assessed. Increased PrPSc deposition (Fig 7B), synap-
tic damage (Fig 7C and S7 Fig), neuroinflammation (Fig 7D) and spongiform degeneration
(Fig 7E) were detected in the cortex compared to the CB of the tg340 infected mice. These data
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Fig 6. Analysis of commonly altered miRNAs in sCJD, AD, DLB and FFI. (A) Venn diagrams of the comparison between altered
miRNAs in AD and sCJD. Commonly deregulated miRNAs in the PFC of AD cases obtained from small RNA-seq analysis (20) (blue
circles) and in the FC of sCJD cases obtained from small RNA-seq analysis in the present work (yellow circles). Common elements and
percentage of maximal coincidence between groups are shown. Among these, the deregulated expression levels of miRNA-195-5p,
miRNA-877-5p and miRNA-323a-5p (marked in red) were previously validated by qPCR in the FC of sCJD cases (Fig 2). (B) RT-qPCR
analysis for miRNA-146a-5p, miRNA-195-5p, miRNA-342-5p, miRNA-877-5p, miRNA-323a-5p and miRNA-5701 in the FC of
controls (n = 5), AD (n = 8) and rpAD (n = 6) cases. (C) RT-qPCR analysis for miRNA-146a-5p, miRNA-195-5p, miRNA-342-5p,
miRNA-877-5p, miRNA-323a-5p and miRNA-5701 in the FC of controls (n = 5) and DLB (n = 5) cases. (D) RT-qPCR analysis for
miRNA-342-5p, miRNA-146a-5p, miRNA-195-5p and miRNA-5701 in the FC and CB of controls (n = 3) and FFI cases (n = 3). Results
were normalized to the housekeeping U6 snRNA expression, which remained unaltered between groups. Normalization was performed
relative to controls. Error bars indicate SD. In all cases, statistical significance (compared to controls) was set at p<0.05.
https://doi.org/10.1371/journal.ppat.1006802.g006
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Fig 7. Regional and temporal-dependent neuropathological characteristics and miRNA signatures in the sCJD MM1 mouse model
tg340-PRNP129MM. (A) tg340 mice were inoculated with control or sCJD MM1 homogenates; cortex and CB samples were collected at
different time points: 120 dpi for pre-symptomatic phase and 160 dpi, 180 dpi and 210 dpi for symptomatic phase (n = 4–5 per group). Animals
sacrificed at 210 dpi were inoculated with a 10–1 inoculum dilution. (B) PET-blot analysis for the detection of PrPSc in the cortex and CB of sCJD
MM1 inoculated tg340 mice at clinical disease stage. (C) Densitometric analysis of western blots developed for PSD-95 and synaptophysin in the
cortex and CB of tg340 samples at different disease stages. Significant alterations on PSD-95 and synaptophysin levels between control and sCJD
inoculated animals is indicated. Statistical significance was set at p<0.05, (n = 4–5 per group). (D) Heat map analysis of key inflammatory
mediators and cytokines measured with RT-qPCR analysis in the cortex and CB of control and sCJD MM1 inoculated tg340 mice at different
stages of the disease. Fold change between sCJD MM1 infected and control animals is shown. (E) Hematoxylin-eosin staining in the cortex and
CB of control and sCJD MM1 infected tg340 animals. (F) RT-qPCR analysis of the miRNAs validated in human sCJD tissue in the cortex and CB
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confirmed the region specific alterations of sCJD MM1 subtype in the tg340, resembling the
most prominent cortical pathology in human sCJD MM1 [5,59]. Next, the expression levels of
the qPCR-validated miRNAs in sCJD were analyzed in a temporal manner (Fig 7F). Ten and
eleven miRNAs were validated in the cortex and in the CB at one of the clinical stages (180
and/or 210 dpi), respectively. Among these, seven were commonly changed in both regions, in
agreement with data from sCJD MM1. An interesting observation from our qPCR panel was
the temporal specific alterations of the sCJD-related miRNAs, since only miRNA-16a-5p
(increased) and miRNA-124-3p (decreased) showed altered levels at early clinical stages of the
disease in the cortex (Fig 7F and S8 Fig). This indicates that qPCR validated miRNAs are
reflecting late pathogenic alterations, while miRNA-16a-5p and miRNA-124-3p may also par-
ticipate in early pathogenic mechanisms. In agreement with this, functional enrichment analy-
sis from small RNA-Seq indicates that the main common functions related to the sCJD-
regulated miRNAs are cell death and survival (S5 Table).
These results suggested that diverse deregulated miRNA, rather than a specific miRNA
deregulation, could contribute to the pathological mechanisms in sCJD. Therefore, we highly
purified miRNAs from the FC of control, sCJD MM1 and VV2 brains and transfected them
into neuroglioma (H4) and differentiated neuroblastoma (SH-SY5Y) cells. Five miRNAs were
analyzed with qPCR in both cell lines, resembling the disease subtype profiling in human sCJD
brain (S9A Fig). Overexpression of sCJD-MM1 purified miRNAs lead to an increased cell
death in neuroblastoma, but not in neuroglia cells (S9B Fig), indicating that the overexpression
of the sCJD regulated miRNAs is able to induce subtype specific cell death in neuron-like cells.
Finally, to gain insight into the potential upstream regulators of differential miRNA expression
in sCJD a motif enrichment analysis was performed for data generated from FC of sCJD MM1
sequencing. Among the known sCJD related pathways, our analysis revealed a significant
enrichment of a STAT3-binding motif for miRNAs with increased expression in sCJD (S6
Table). This suggests that the expression of sCJD-specific miRNAs is under STAT3 regulation,
which has been described as activated not only in experimental models of prion diseases
[60,61], but also in sCJD post-mortem tissue [5].
Differential miRNA expression levels of abundant CSF miRNAs in sCJD
CSF miRNAs have been suggested as a source of biomarkers in neurodegenerative disease mir-
roring alterations in the brain tissue [62,63]. Thus, we aimed to investigate whether the
detected miRNA alterations in the brain tissue of sCJD patients could be reflected in the CSF.
CSF RNA was extracted from twelve control and twelve sCJD cases and was subjected to
qPCR analysis for the following miRNAs: 154-5p, 204-5p, 378a-3p, 331-3p, 26a-5p, 195-5p,
124-3p, 7i-3p, 143-3p, 449a and 5701. For normalization we used the non-coding small nuclear
RNA U6, which showed stable levels between control and sCJD cases (Fig 8A). Detectable sig-
nal (35<Cts) was obtained for miRNAs 378a-5p, 26a-5p and 204-5p, with miRNA-204-5p
showing significantly decreased levels in sCJD compared to controls (Fig 8B).
Discussion
In the present study, we report the first systematic analysis of miRNA populations in two brain
areas and two disease subtypes of sCJD cases, utilizing small RNA-seq analysis. We detected
of tg340 mice. Samples from different time points of disease progression were analyzed. Fold change between sCJD MM1 infected and control
animals is shown. Results were normalized to the housekeeping gene U6 snRNA expression. U6 levels remained unaltered between groups.
Normalization was performed relative to controls. Error bars indicate SD. In all cases, statistical significance (compared to controls) was set at
p<0.05.
https://doi.org/10.1371/journal.ppat.1006802.g007
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marked alterations in miRNA patterns with the presence of regional and sCJD-subtype specific
signatures, with highest deregulations in the FC of MM1 and in the CB of VV2 cases, two
brain regions and subtypes showing high pathological affection in sCJD [1]. In this regard, the
low overlap between sCJD subtypes altered miRNAs in CB and FC could be explained by the
singular pathology of sCJD VV2 in CB, where characteristic PrPSc aggregates (synaptic and
plaque-like) and degree of spongiform degeneration, neuronal loss and neuroinflammation
profiling are detected [5–7], following classical well-known sCJD regional and subtype-depen-
dent molecular neuropathology [2,47,64].
Small RNA-seq provides a blind and unbiased approach to the study of the small RNA tran-
scriptome. However, a limitation of this technique is the presence of potentially biased fold
changes when number of counts is low. Therefore, confirmatory analysis by qPCR is indis-
pensable to consistently validate the regulation of selected targets. The enrichment of regulated
miRNAs in Ago-containing complexes, as well as a severe, global reduction of miRNA expres-
sion levels in sCJD compared to controls described herein, supports the idea that alterations in
expression levels are translated into the functional miRNA silencing machinery. Small RNA-
seq also revealed length and sequence heterogeneity for the vast majority of miRNAs. How-
ever, the fact that the proportion of different miRNA variants detected by isomiR profiling was
similar in all cases indicates that the molecular mechanisms involved in isomiR generation are
not altered in sCJD, similarly to the situation previously reported for HD [15].
Data on miRNA alterations in sCJD are limited to two targeted studies, including very small
cohorts of cases. Upregulation of miRNA-146a-5p in the neocortex of sCJD cases (n = 3 sCJD,
n = 3 controls) [65] and upregulation of miRNA-342-3p in sCJD brain tissue (n = 2 sCJD, n = 1
control) [23] are in agreement with our observations. In contrast, several studies have been
devoted to analysing the miRNAome in prion animal models. A lack of major correlation
between regulated miRNAs in sCJD and scrapie-infected mice was detected in high-throughput
studies. However, miRNAs: 146a-5p, 342-3p, 142-3p, 26a-5p, 124a-3p (RNA-seq altered and
qPCR validated in sCJD) and 338-5p, 18a-3p, 455-5p, 182-5p (RNA-seq altered in sCJD) are
commonly altered in at least one of the studies where scrapie miRNA profiles have been investi-
gated [21–23,25,33,66]. Additionally, two miRNAs upregulated in the basis pontis of bovine
spongiform encephalopathy-infected macaques, miRNA-342-3p and miRNA-494-3p [23], were
also enriched in sCJD, but exclusively in the FC region. Although low co-occurrence on
miRNA profiles may be due to different methodologies, the absence of detailed regional studies
in mouse models and the specific prion-related pathology in humans may explain this diver-
gence. Altogether, these data highlight the importance of detailed regional and disease-subtype
studies in prion diseases. Yet, intra-species comparisons are now achievable through the study
of humanized PRNP mouse models, which not only fully recapitulate pathological hallmarks of
human disease [5,59] but also, as reported in the present study, resemble human miRNA profil-
ing. In this regard, alterations in miRNA signatures in tg340 at clinical stages are not detectable
at pre-clinical stages. This finding, along with the presence of enriched miRNA-target genes
related to cell death and survival, indicates that sCJD-regulated miRNAs may play a role in the
molecular mechanisms related to the neurodegenerative process and that a different population
of miRNAs, would be responsible for the primary causative events of the disease.
Relative decreased mature miRNA levels in sCJD are consistent with decreased expression
levels of Dicer, Drosha and DGCR8. The miRNA biogenesis pathway is highly conserved and
Fig 8. miRNA profiling in the CSF of control and sCJD cases. RT-qPCR analysis of the housekeeping U6 snRNA (A)
and miRNA-378a-3p, miRNA-26a-5p and miRNA-204-5p (B) in the CSF of control (n = 12) and sCJD cases (n = 12).
Samples were normalized by the relative expression of the housekeeping small nuclear RNA U6, which showed stable
Ct values between the studied groups. Statistical significance was set at p<0.05.
https://doi.org/10.1371/journal.ppat.1006802.g008
microRNAs in Creutzfeldt-Jakob disease
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006802 January 22, 2018 17 / 33
its disruption is a well-reported cause of neurodegeneration. Loss of Dicer levels provokes neu-
ronal dysfunction in Purkinje cells [67], dopaminergic neurons [68] and motor neurons [69],
and increased excitability of CA1 pyramidal neurons [70] while compromising axonal integ-
rity in Schwan cells [71]. In addition, Dicer protein levels have been found to be decreased in
temporal lobe epilepsy patients with hippocampal cell loss, with about half of the miRNAs in
the tissue displaying reduced levels [72]. Finally, similar to our observations, impaired miRNA
biogenesis at Dicer level associated with downregulation of miRNA levels and reorganization
of Dicer and Ago-2 complexes has recently been described in amyotrophic lateral sclerosis
[73] suggesting that miRNA malfunction could be a contributor to pathogenesis associated
with protein-misfolding associated diseases. Interestingly, lack of expression changes in Expor-
tin 5 suggests that changes detected in the miRNA expression profiles in sCJD are most likely
not due to alterations in the nuclear export of pre-miRNA.
Whether alterations of miRNA biogenesis and homeostasis in sCJD are primary factors in
the neurodegenerative phenotype of the disease due to dysfunctional miRNA maturation, or
are a consequence of the pathology, deserves further studies.
Besides highlighting alterations in miRNA biogenesis and network, our results also reveal a
remodelling of the miRNA-mRNA silencing complexes in sCJD. This is sustained by partial
re-distribution of Ago-2 to higher molecular weight chromatographic fractions, increased Ago
nuclear reactivity, presence of Ago-2 positive microglial cells and increased expression of
p-body marker dcp1 in sCJD brain tissue. Ago-2 and RISC components have recently been
found in the nucleus of humans and Drosophila and associated in multi-protein complexes
with functional silencing activity over nuclear targets [74,75], as well as with additional func-
tions in pre-mRNA splicing and transcriptional repression [75]. The role of Ago proteins,
especially Ago-2, in prion pathology deserves attention not only due to its differential localiza-
tion in sCJD, potentially altering its physiological functions, but also because PrPC has been
described as an Ago-2 interacting partner, promoting the accumulation of miRNA-RISC effec-
tor complexes [26]. PrPC is internalised into the endocytic recycling pathway and most of the
molecules are recycled intact to the cell surface [76]. Since late endosomes and/or multivesicu-
lar bodies are the main site for intracellular conversion of PrPC to PrPSc, and RISC formation
and/or turnover depends on the endosomal pathway [77,78]; the detection of PrPSc in Ago-2
complexes provides a link between RNA silencing and membrane trafficking in sCJD patho-
genesis. Additionally, a translocation of Ago-2 from cytoplasm to nuclear fractions in sCJD
would alter, and potentially impair, the silencing of cytoplasmic mRNA targets by the RISC
complex.
As additional modifiers of the miRNA-mRNA silencing complexes in sCJD we investigated
the presence of SG, which appear in the cell under stress conditions such as oxidative and
endoplasmic reticulum stress [79,80], two well-known sCJD hallmarks [41,81]. Although both
p-bodies and SG may support overlapping cellular functions and share components, they are
not equivalent and they are spatially distinct. SG are thought to be responsible for mRNA stor-
age as these sites lack the decapping enzyme [82], and their formation is mediated through
phosphorylation of eIF2α and aggregation of Tia-1 [83,84]. Neither increased eIF2α phosphor-
ylation nor altered levels of SG markers were detected, suggesting that SG are not specific
structures in sCJD.
A surprising finding of our study was the absence of massive reduction of neuronal-
enriched miRNAs levels, indicating high miRNA stability in brain after neuronal death. An
exception to this was the decreased levels of miRNA-124-3p, also decreased in experimental
models of prion diseases [21,22,66]. In situ hybridization supports the idea that miRNA-124-
3p is not merely decreased as a consequence of neuronal death, since surviving neurons
express less miRNA-124-3p compared to those from controls, pointing towards a specific role
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for this miRNA in sCJD pathology. miRNA-124-3p is the most abundant miRNA in the brain
and promotes neuronal differentiation and maintenance of neuronal identity [85]. In AD, its
expression is decreased in the anterior temporal cortex [86], decreased in the dentate gyrus,
and upregulated in the locus coeruleus [87]. In an ex vivo model of PD, miRNA-124-3p is
decreased regulating apoptosis and impaired autophagy [88]. This plethora of evidence
denotes a functional role of miRNA-124-3p in neurodegeneration.
In fact, our study details the existence of common miRNA traits in the cortical region of
AD, DLB and sCJD. There is virtually no information on the functions of the two commonly
regulated miRNAs in the brain of the three dementias (miRNA-877-5p and miRNA-323a-5p).
On the contrary, miRNA-195-5p, elevated in AD and sCJD, downregulates Aβ production by
targeting APP and BACE1, and protects against chronic brain hypoperfusion-mediated
dementia [89]. Its overexpression also led to reduced BACE1 and decreased Aβ levels in an
independent study [90]. Although the precise role of miRNA-195-5p in prion diseases is
unknown, we also detected increased levels in the FC of fatal familial insomnia (FFI), a genetic
prion disease with moderate cortical involvement [91].
Based on the conception that one miRNA can target multiple mRNAs and one mRNA can
be targeted by multiple miRNAs, our results support multiple lines of evidence indicating that
the result of the intricate alterations in miRNA networks and clusters, rather than representing
a change in the expression of a single miRNA, are responsible for pathological phenotypes
[92–94]. Thus, the precise miRNA homeostasis in sCJD brain would underlie the spectrum of
molecular and phenotypic cues, in agreement with the acquisition of a disease-related pheno-
type by a neuronal-like cell line upon transfection with the sCJD-associated miRNA
transcriptome.
CSF miRNAs may reflect alterations in brain pathology of neurodegenerative diseases.
Indeed, miRNA profiling in AD and PD correlates with disease status and pathological fea-
tures [63,95] but less is known about the levels of brain-regulated miRNAs in the CSF. Our tar-
geted study revealed that only miRNAs with reported high CSF expression levels were
detectable [96]. Of these, only miRNA-204-5p displayed decreased levels in sCJD cases. Inter-
estingly, this miRNA was not statistically regulated in sCJD brain. Our findings are in line
with those reported in AD, where no obvious relationship between altered miRNAs in CSF
and pathologically affected brain regions was found [17,95]. As the reason for this lack of cor-
relation is unknown, it is tempting to speculate that different disease stages between CSF and
brain sample collection (time of diagnosis for CSF versus post-mortem for brain tissue) may
contribute to these differences. Additionally, as the origin of CSF miRNAs is not well under-
stood, CSF miRNAs may originate not only from brain, but also from extracraneal tissues.
In summary, our study presents, for the first time, comprehensive miRNA signatures in
human prion diseases and unravels the complex network of regional and disease-subtype
miRNA alterations in sCJD, as well as revealing the presence of a disturbed miRNA biogenesis
pathway and miRNA-mRNA silencing machinery. It also highlights the existence of time-
dependent miRNA profiles along disease duration and identifies commonly altered miRNAs
between several dementias sharing a partial clinical overlap. Taken together, the present data
shed light on the potential role of miRNAs as a contributing factor and/or transmitters of path-
ogenic molecular traits in sCJD.
Materials and methods
Reagents
List of Taqman probes assays, Exiqon primer sets and antibodies is given in S7 Table. Lipofec-
tamine 2000 was from Thermo Fisher Scientific. Thioflavin and Propidium Iodide were from
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Sigma. WST-1 was from Roche. TruSeq Small RNA Sample Preparation Kit was from Illu-
mina. CHROMA SPIN-200 spin columns were from Clontech and Protein G magnetic beads
were from Invitrogen.
Cases and general processing
Brain tissue processing has been described before [5–7,97]. Mean ages and gender for studied
control and sCJD cases, for RNA-seq, qPCR and western blot analysis are detailed in S8 Table.
Information on the mean ages and gender for the AD, DLB and FFI samples that were ana-
lysed with RT-qPCR in the present study are as below: For AD analysis: Control = 75 (3M/2F),
AD = 76 (4M/4F) and rapid progression AD (rpAD) = 77 (3M/3F). rpAD cases were AD cases
with disease duration shorter than 2 years. For DLB analysis: Control = 71 (3M/2F), DLB = 75
(3M/2F). For FFI analysis: Control = 58 (2M/1F), FFI = 52 (2M/1F). Biochemical studies
including sCJD and FFI cases were performed in biosafety rooms (S3 level). mRNA and
miRNA levels were associated neither to RNA integrity number (RIN) values nor to post-mor-
tem time. Protein levels were not associated to post-mortem time.
CSF samples were obtained from an unrelated series of patients with sCJD and from con-
trols. sCJD patients diagnosed with probable or definite sCJD according to established criteria
were considered for the sCJD group [98]. The control group was composed of patients suffer-
ing from neurological conditions (S9 Table). The presence of neurodegenerative diseases in
the control cohort was excluded in the follow-up clinical diagnostic, and CSF neurodegenera-
tive biomarkers (14-3-3, tau, p-tau and Aβ42) were negative at the time of diagnosis.
CJD subtype characterization
PRNP codon 129 genotyping (Met or Val) was performed after genomic DNA isolation from
blood samples according to standard methods [99]. Western blot PrPSc profile was classified
as type 1 (un-glycosylated PrPSc at 20 kDa) or type 2 (un-glycosylated PrPSc at 19 kDa), based
on electrophoretic mobility after proteinase K (PK) digestion [4,64].
RNA extraction and sequencing
The purification of RNA from FC and CB of CJD and age-matched controls was performed
using the mirVana isolation kit (Ambion, US) according to the manufacturer’s instructions.
After purification, samples were treated with the RNase-free DNase set (Ambion, US) for 30
min to avoid carry over and subsequent amplification of genomic DNA. The concentration of
each sample was determined using the NanoDrop 2000 spectrophotometer (Thermo Scien-
tific, US). RNA integrity number (RIN) was verified with the Agilent 2100 Bioanalyzer (Agi-
lent, US). The threshold for further sample selection was set to RIN value equal to or greater
than 5.5. Starting from 1 μg of total RNA, libraries were prepared following the TruSeq Small
RNASample Preparation Guide protocol from Illumina (Part # 15004197 Rev. E). Library
quality was assessed on the Agilent Technologies 2100 Bioanalyzer. DNA was loaded into a
lane of a single-read flow cell at a concentration of 3–3.5 pM for cluster generation using a sin-
gle-read cluster generation kit (Illumina). From 13 to 15 barcoded samples were sequenced
per lane. The sequencing primer (50-CGACAGGTTCAGAGTTCTACAGTCC GACGATC-30)
was annealed to the clusters and the flow cell was then mounted on a Hiseq 2000 instrument
(Illumina) for sequencing, and 36–41 sequencing cycles were performed. A PhiX control lane
loaded at a concentration of 2 pM was used to monitor run quality. Image processing and base
calling was performed using Illumina sequencing analysis pipelines v0.3.0 or v1.3.2. A total of
72 samples were analyzed by small RNA-seq: For FC 13 controls, 13 sCJD MM1 and 13 sCJD
VV2 were analyzed for CB: 12 controls, 12 sCJD MM1 and 9 sCJD VV2.
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Small RNA data processing and mapping
Reads were trimmed to 36 nt and ligation adapters were removed using the adrec.jar program
from the seqBuster suite (http://github.com/lpantano/seqbuster) [28] with the following
options: java -jar adrec.jar 1 8 0.3. Sequences were mapped to the hg19 genome with the com-
mand line: bowtie -f -v 1 –a–best–strata. For summing up miRNA read counts we mapped the
reads against miRBase version 21 hairpins with the miraligner.jar tool with these options:
java–jar miraligner.jar 1 3 3.
Out of a total of several million reads, we discarded any reads without a minimum of 10-nt
linker subsequence directly adjoining the insert, showing two or less mismatches. Then
sequences were mapped to human pre-miRNA and mature miRNA databases provided in the
miRBase (http://miRNA.sanger.ac.uk/sequences/, Release 14), as well as mRNA, ncRNA,
repeats and genome databases available at (http://hgdownload.cse.ucsc.edu/goldenPath/hg18/
bogZips/), using Mega BLAST.
For motif discovery, deregulated miRNAs were searched for the genomic coordinates of
their primary miRNAs. Upstream regions of 1kb size from each miRNA were extracted and
exported to BED files and the script findMotifsGenome.pl in HOMER suite was used to find
transcription factor binding motifs within promoter regions using genome assembly hg38 [100].
For differential expression analysis we used DESeq2 analysis and log2 transformation of the
count data. Padj value was<0.15 and nominal p values were in all cases <0.05. We used the
count matrix generated by Seqbuster. Only miRNAs consistently expressed (counts > 10) in at
least 10 samples out of the 21–26 were included in each analysis (controls versus MM1 or VV2
cases).
Analysis of miRNA variability (IsomiRs)
IsomiRs were annotated and analyzed using the SeqBuster tool [28]. For miRNA annotation
the following parameters were configured: one mismatch, 3 nts in the 3’ or 5’-trimming vari-
ants, 3 nts in the 3’-addition variants. These options permitted annotations of the following
types of alignment: (i) perfect match, where the sequence is completely identical to the refer-
ence sequence; (ii) trimming at the 3’-end of the reference miRNA sequence, which is an
miRNA variant several nucleotides shorter or longer that matches to the mature or precursor
reference sequence, respectively; (iii) trimming at the 5’-end of the sequence, an analogous
case as to (ii) but focused on the 5’-end of the miRNA; (iv) nucleotide additions at the 3’-end
of the sequence and (v) nucleotide substitutions, showing nucleotide changes with respect to
the reference sequence. The parameters for the alignment to the mRNA and genome databases
allowed up to one mismatch and up to three nucleotide additions in the 3’-terminus.
For deep characterization of IsomiRs we applied several filters. First, the sequences consid-
ered in the analysis presented a frequency above 3. Second, 10 was chosen as the ‘Contribution
Cut-Off’ parameter, meaning that every isomiR considered in the analysis contributes by more
than 10% to the total number of variants annotated in the same miRNA locus. Third, we
applied the Z-score option to exclude sequencing errors as the possible cause of the nucleotide
changes observed in some variants.
miRNA purification for transfection experiments
RNA samples extracted with the mirVANA isolation kit (Ambion) using the specific protocol
for small RNA isolation were run on a 6% Urea–PAGE. The bands containing miRNAs (15–
30 nt) were excised from the gel and incubated for 1 hour with 250 mM NaCl and 1 mM
EDTA. miRNAs were then precipitated with 2.5 volumes of 100% ethanol (v/v) over night at
−80˚C, washed twice with 70% ethanol and re-suspended in nuclease-free water.
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Cell cultures and transfection
H4 and SH-SY5Y cells (American Type Culture Collection) were cultured at 37˚C in a 95%/
5% Air/CO2 water-saturated atmosphere in Dulbecco’s modified Eagle’s medium (DMEM,
Thermo Fisher Scientific) containing 10% heat inactivated fetal bovine serum (FBS, Thermo
Fisher Scientific), 2 mM L-glutamine and 100U/ml Penicillin/streptomycin (Gibco). SH-SY5Y
cells were differentiated with DMEM containing 3% FBS and 10 μM all-trans retinoic acid
(RA, Sigma) for 72 hours. Differentiation medium was replenished after 48 hours. Cells were
transfected with 250 ng of highly purified miRNAs with Lipofectamine 2000 (Invitrogen) fol-
lowing the manufacturer’s instructions.
Gel filtration
Analysis of protein fractions according to their molecular weight was performed as described
before [36] using CHROMA SPIN-200 (Clontech, USA) spin columns. Columns were pre-
spun at 200xg for 3 min to remove storage buffer. Buffer exchange was made by the addition
of 500 μl lysis buffer followed by centrifugation at 200 xg for 3 min. This step was then
repeated. 75 μl of 1% brain homogenates were applied to the gel bed. After spinning at 120 xg
for 2 min elution fractions were collected, and 40 μl of extraction buffer was added after each
centrifugation step.
sCJD MM1 mice–tg340 PRNP129MM
The tg340 mouse line expressing about 4-fold level of the human PrP M129 on a mouse PrP
null background was generated as described elsewhere [59]. Control and sCJD MM1 brain tis-
sues (10% (w/v) homogenates) were used as inocula. Individually identified 6–10 week-old
mice were anesthetized and inoculated in the right parietal lobe using a 25-gauge disposable
hypodermic needle. Additionally, MM1 inoculum dilutions were performed to study pro-
longed disease times; animals were sacrificed at 210 dpi (10–1 dilution). Mice were observed
daily and their neurological status was assessed weekly. The animals were euthanized at pre-
symptomatic (pre-clinical: 120 dpi) and symptomatic (early clinical: 160 dpi and clinical: 180
dpi) stages and the brain was removed. A part of the brain was fixed by immersion in 10%
buffered formalin, to quantify spongiform degeneration and perform immunohistological
analysis. The other part was frozen at −80˚C, for extraction of protein and RNA. Paraffin-
embedded tissue blots from tg340 mice samples was carried out as described previously [5].
For each tissue sample, serial sections, 4 mm thick for PET blot, were collected on membranes.
Serial sections were stained with hematoxylin and eosin. SHa31 antibody was used for PrP
immunodetection.
RT-qPCR
In order to confirm the direction of the miRNA alterations detected by RNA-seq in sCJD cases
(increased or decreased levels compared to controls) by an independent methodology qPCR
analysis of selected miRNAs was performed. Quantitative real time PCR for miRNAs was per-
formed using the miRCURY LNAmiRNA PCR System (Exiqon) following Minimum Infor-
mation for Publication of Quantitative Real-Time PCR Experiments guidelines. RNA was
extracted with the mirVana isolation kit (Ambion) following the manufacturer’s instructions.
PCR amplification and detection were performed with the Roche LightCycler 480 detector,
using 2x SYBR GREEN Master Mix. The reaction profile was: Polymerase Activation/Denatur-
ation (95˚C for 10 min) followed by 40 amplification cycles (95˚C-10 sec, 60˚C-20 sec).
miRNA levels were calculated using the LightCycler 480 software. Samples were normalized
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by the relative expression of the housekeeping small nuclear RNAs U6 and U5. Housekeeping
genes showed no variability between analyzed groups. CT values obtained from the miRNA
qPCR analysis ranged from 18 to 31.
Quantitative real time PCR for mRNAs was performed using Taqman probes (Life Tech-
nologies) on total RNA extracted with mirVana’s isolation kit (Ambion) following the manu-
facturer’s instructions. PCR assays were conducted in duplicate using cDNA samples obtained
from the retrotranscription reaction and diluted 1:15 in 384-well optical plates. PCR amplifica-
tion and detection were performed with the Roche LightCycler 480 detector, using Taqman
Universal PCR Master Mix, following the manufacturer’s instructions. The reaction profile was
as follows: denaturation–activation cycle (95˚C for 10 min) followed by 40 cycles of denatur-
ation–annealing–extension (95˚C, 10 min; 72˚C, 1 min; 98˚C, continuous). mRNA levels were
calculated using the LightCycler 480 software. Samples were normalized based on the relative
expression of a housekeeping gene (glyceraldehyde-3-phosphate dehydrogenase [GAPDH]).
The housekeeping gene showed no variability between analyzed groups.
Western blot
Human tissues were lysed in lysis buffer: 100 mM Tris pH 7, 100 mM NaCl, 10 mM EDTA,
0.5% NP-40 and 0.5% sodium deoxycolate plus protease and phosphatase inhibitors. After cen-
trifugation at 14,000g for 20 min at 4˚C, supernatants were quantified for protein concentra-
tion (BCA, Pierce), mixed with SDS-PAGE sample buffer, boiled, and subjected to 8–15%
SDS-PAGE. Gels were transferred onto nitrocellulose membranes and processed for specific
immunodetection by chemiluminescence (ECL Amersham, US) using the indicated antibod-
ies. Densitometries were carried out with the ImageJ software and values were normalized
using β-actin levels.
RISC immunoprecipitation
Protein G magnetic beads were pre-equilibrated in lysis buffer (150 mM NaCl, 50 mM Tris,
0.5% NP40, protease and phosphatase inhibitors) and mixed with 1 mg of human FC brain
homogenate from either control or sCJD MM1 cases and with 4 μg of Ago antibodies 11A9 or
H-300. As a control, 4 μg of an unspecific IgG antibody was used. Complexes were incubated
overnight at 4˚C with gentle end-to-end shaking. To extract the immunoprecipitated RNA,
beads were washed three times in lysis buffer and resuspended in phenol-chloroform. The
RNA in the aqueous phase was precipitated for 1 h at -80˚C after addition of 2.5-fold volume
ethanol and 0.1-fold volume NaAc (3mol/l); precipitated RNA was pelleted by centrifugation
for 25 min at 4˚C at 20,000xg. After washing in cold 70% ethanol, centrifugation and air dry-
ing, RNA was re-suspended in 10 μl of RNase-free water. The miRCURY LNA Universal RT
miRNA PCR kit (Exiqon) was used for miRNA reverse transcription. For this, 6.5 μl of re-sus-
pended RNA was applied in a total RT reaction volume of 10 μl (2μl 5x reaction buffer, 1μl
enzyme mix, 0.5μl nuclease free water). cDNA was synthesized as described before for miRNA
RT. A 1:80 cDNA dilution was used for miRNA quantification via real-time PCR amplification
and miRNA LNA primer sets.
miRNA in situ hybridization
For miRNA recognition locked nucleic acid (LNA) modified probes combined with signal
amplification technology using enzyme-labeled immunoassay were obtained from Exiqon
(Vedbaek, Denmark). The following double digoxigenin (DIG)-labelled sequences of the LNA
probes were used: hsa-miRNA-124: 5’-DIG/ggcattcaccgcgtgcctta/DIG-3’, hsa-miRNA-146a 5’-
DIG/aacccatggaattcagttctca/DIG-3’, has-miRNA-26a 5’-DIG/agcctatcctggattacttgaa/DIG-3’.
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The sequence of the U6 snRNA positive control probe was: 5’-DIG/cacgaatttgcgtgtcatcctt/-3’.
6 μM-thick brain tissue sections were deparaffinised, deproteinized with Proteinase K (15μg/
ml) at 37˚C for 10 min, washed in PBS and dehydrated in increasing concentrations of ethanol.
Probe hybridization was performed over night at 55˚C with 100 nM (hsa-miRNA-146a, hsa-
miRNA-26a), 40 nM (miRNA-124), or 1 nM (U6 snRNA) of LNA probe diluted in hybridiza-
tion mix. After stringent washing in salt sodium citrate (SSC) buffer and blocking with 2%
sheep serum/1% bovine serum albumin, probe-target complex was visualized immunologically
with anti-DIG antibody (Roche, 1:800) conjugated to alkaline phosphatase acting on the chro-
mogen NBT/BCIP. In some cases, slides were counterstained with nuclear fast red (Vector
laboraties). For quantification of miRNA-124-3p, 3 controls and 2 sCJD MM1 cases were
used.
Immunofluorescence
For immunofluorescence analysis in brain tissues, de-waxed sections, 4 microns thick, were
stained with a saturated solution of Sudan black B (Merck, DE) for 15 min, to block the auto-
fluorescence of lipofuscin granules present in cell bodies, and then rinsed in 70% ethanol and
washed in distilled water. The sections were boiled in citrate buffer to enhance antigenicity
and blocked for 30 min at room temperature with 10% fetal bovine serum diluted in PBS.
Then, the sections were incubated at 4˚C overnight with primary antibodies. After washing,
the sections were incubated with Alexa488 or Alexa546 (1:400, Molecular Probes, US) fluores-
cence secondary antibodies against the corresponding host species. The sections were
mounted in Immuno-Fluore mounting medium (ICN Biomedicals, US), sealed, and dried
overnight. Sections were examined with a Leica TCS-SL confocal microscope.
Real time quaking induced conversion (RT-QuIC)
RT-QuIC was performed as previously described [101] with minor modifications. Briefly,
recombinant PrP (10 μg) was seeded with 15 μl of Ago-2-Immunoprecipitates in 85 μl of reac-
tion buffer. Reaction was set in a final volume of 100 μl and placed in a 96-well black optical
bottom plate (Fisher Scientific). Each sample was run in duplicate. Prepared plates were sealed
and incubated in a FLUO Star OPTIMA plate reader (BMG Labtech Ortenberg, GE) at 42˚C
for 80 h, with intermittent shaking cycles consisting of 1 min double orbital shaking at the
highest speed (600 rpm) followed by a 1 min break.
CSF analysis
Lumbar punctures were performed for diagnostic purposes at the time point of the first diag-
nostic work-up and samples were stored at −80˚C until analysis. 14-3-3 protein was analyzed
as described previously [102] and total tau was quantitatively measured using the enzyme-
linked immunosorbent assay kits INNOTEST-hTAU-Ag from Fujirebio according to the
manufacturer’s instructions. RT-QuIC analysis was performed as described before [101]. RNA
purifications from CSF were performed using miRCURY RNA Isolation Kit–Biofluids (Exi-
qon) following manufacturer-provided protocol with minor modifications. 200 μl CSF input
volume was used and treated with 2 μg/μl Proteinase K in order to optimize the RNA yield. As
an inert RNA carrier 2 μg Glycogen per CSF sample was added. The miRCURY LNA Univer-
sal RT miRNA PCR kit (Exiqon) was used for miRNA reverse transcription. For this, 4 μl of
re-suspended RNA was applied as input in a total RT reaction volume of 10 μl (2 μl 5x reaction
buffer, 1 μl enzyme mix, 3 μl nuclease free water) and cDNA was synthesized as described
before for miRNA RT. A 1:80 cDNA dilution was used for miRNA quantification via real-time
PCR amplification and miRNA LNA primer sets. The small RNA U6 revealed to be stable
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in CSF samples from sCJD and control samples and was used as reference gene for miRNA
quantification.
Statistical analysis
For comparisons of the two groups, the Mann-Whitney test was used. In multiple compari-
sons, the Kruskal-Wallis test was used. Dunn’s multiple comparison test was used for post hoc
analysis. Statistical analyses and calculations were carried out using GraphPad Prism 5 soft-
ware. Statistical significance was set at p<0.05.
Ethics
Brain tissue samples were obtained from the Institute of Neuropathology Brain Bank (HUB-I-
CO-IDIBELL Biobank) and the Biobank of Hospital Clinic-IDIBAPS, following pertinent
guidelines of the Spanish legislation and the local ethics committee. The present study was
conducted according to the revised Declaration of Helsinki and Good Clinical Practice guide-
lines and was approved by the local ethics committees (University of Göttingen -No. 9/6/08,
19/11/09 and 18/8/15). Informed written consent was given by all study participants or their
legal representative. All participants were adults, and samples were anonymized.
For animal investigation, principles of laboratory animal care (NIH publication No. 86–23,
revised 1985) were followed. All animal experiments were performed in compliance with the
French, national guidelines, in accordance with the European Community Council Directive
86/609/EEC. The protocols comply with the Animal Research: Reporting In Vivo Experiments
(ARRIVE) guidelines. The experimental protocol was approved by the INRA Toulouse/ENVT
ethics committee (Permit number: 310955547).
Supporting information
S1 Fig. MA plots from small RNA-Seq in the FC and CB of control, sCJD MM1 and VV2
cases. Plots represent the log2 fold change over the mean expression of mean normalized
counts for each group comparison.
(TIF)
S2 Fig. Distribution of the different types of isomiRs in control and sCJD. IsomiR distribu-
tion in control individuals (red) and MM1 or VV2 samples (blue), in the FC (A-B) and the CB
(C-D). The size of the dots shows the relative abundance of the different types of isomiRs. The
Y-axis shows the fraction of unique sequences affecting specific nucleotides along the miRNAs,
indicated in the X-axis. In the X-axis the nucleotide changes at diverse positions defining the
isomiR are indicated with respect the reference miRNA (the miRbase sequence). For the trim-
ming variants positions with a minus refer positions upstream of the reference miRNA.
(TIF)
S3 Fig. Expression of GW182 in sCJD brain tissue. (A) Gene expression levels of GW182
(n = 10) in the FC and CB of controls, sCJD MM1 and VV2 cases by RT-qPCR. Results were nor-
malized to housekeeping genes GAPDH (figure) and GUSB with similar results. Housekeeping
levels remained unaltered between groups. (B) Protein levels of GW182 in the FC of controls,
sCJD MM1 and VV2 cases, by western blot analysis. Three representative cases per diagnostic
group and brain region are shown in the western blot. Quantifications derived from densitometry
analysis were performed in 15 cases per diagnostic group (n = 15/group). β-actin was used as a
loading control. Densitometries of the western blots (n = 15 cases/group) are shown. Normaliza-
tion was performed relative to controls. Error bars indicate SD. In all cases, statistical significance
(compared to controls) was set at p<0.05. (C) Representative fluorescence photomicrographs of
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GW182 immunoreactivity in the FC of control, sCJD MM1 and sCJD VV2 cases. Phase contrast
and merge images are shown. Scale bar = 25μm.
(TIF)
S4 Fig. Analysis of gel filtration chromatography fractions from sCJD cases. (A) Coomas-
sie-blue staining of the chromatographic gel filtration fractions obtained from the FC of a
sCJD brain homogenate. A representative image of three independent experiments is shown.
Molecular weight and fraction numbers are indicated (B) Western blot analysis of the different
gel filtration fractions using the Prion protein SAF70 antibody. A representative control and
sCJD case is shown. (C) RT-QuIC analysis of the input and chromatographic gel filtration
fractions 2 and 7 obtained from the FC of a control and of sCJD brain homogenate. Positive
signal was only detected in sCJD fractions. Higher signal, as detected by shorter lag phase was
detected in the input, fraction 2 and fraction 7, respectively. A representative image of three
independent experiments is shown. (D) Dot-blot analysis developed against the oligomer anti-
body 11A of the input and chromatographic gel filtration fractions 2 and 7 obtained from the
FC of a control and sCJD brain homogenate. Positive signal was only detectable in sCJD frac-
tions. A representative image of three independent experiments is shown.
(TIF)
S5 Fig. Subcellular localization of Ago-2 in sCJD brain tissue. (A) Representative fluores-
cence photomicrographs of Ago-2 immunoreactivity (11A9 antibody) in the FC of control,
sCJD MM1 and sCJD VV2 cases. Phase contrast and merge images are shown. Scale
bar = 25μm. Representative fluorescence photomicrographs of Ago-2 (11A9 antibody, green
channel) and Iba-1 (red channel) immunoreactivity in the FC of control and sCJD MM1 cases.
Arrowheads indicate absence of Ago-2 expression in microglial cells in control cases. In con-
trast, in sCJD cases some microglial cells are double stained with Ago-2 antibody. Merge
images are shown. Scale bar = 25μm (C).
(TIF)
S6 Fig. Expression of Exportin 5 in sCJD brain tissue. (A) Gene expression levels of Exportin
5 (n = 10) in the FC and CB of controls, sCJD MM1 and VV2 cases by RT-qPCR. Results were
normalized to housekeeping genes GAPDH (figure) and GUSB with similar results. House-
keeping levels remained unaltered between groups. (B) Protein levels of Exportin 5 in the FC
of controls, sCJD MM1 and VV2 cases, by western blot analysis. Two representative cases per
diagnostic group and brain region are shown in the western blot. Quantifications derived from
densitometry analysis were performed in 15 cases per diagnostic group (n = 15/group). β-actin
was used as a loading control. Densitometries of the western blot (n = 15 cases/group) are
shown. Normalization was performed relative to controls. Error bars indicate SD. In all cases,
statistical significance (compared to controls) was set at p<0.05.
(TIF)
S7 Fig. Synaptic loss in the sCJD MM1 mouse model tg340-PRNP129MM. Western blot
analysis of PSD-95 and synaptophysin in the cortex and CB of control and sCJD MM1 inocu-
lated mice at different disease stages. GAPDH was used as a loading control.
(TIF)
S8 Fig. Temporal-dependent expression of validated miRNAs in the sCJD MM1 mouse
model tg340-PRNP129MM. Representation of the miRNAs with regulated expression levels
in the cortex (A) and CB (B) of the tg340 mice by RT-qPCR analysis at any of the different
stages of the disease. Data is represented as the fold change between sCJD MM1 and control
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inoculated animals and each colored line represents a miRNA.
(TIF)
S9 Fig. Selective cell death induction by sCJD miRNAs transfection in cell cultures. (A)
miRNAs from Control, sCJD MM1 and sCJD VV2 cases (FC region) were highly purified using
commercial RNA extraction kits followed by in-gel purification and transfection into SH-SY5Y
RA-differentiated cells and glioblastoma H4 cells. RNA was extracted from the cells and selected
sCJD-related miRNAs were quantified by qPCR. NT: non-transfected. Statistical differences
of comparison with non-transfected cells are indicated; p<0.05. (B) Cell toxicity assay, using
Iodide Propidium staining (PI) on H4 and SY-SY5Y cells at 48h post-transfection with highly
purified miRNAs derived from Control, sCJD MM1 and sCJD VV2 cases (FC region). (C) Cell
viability, using WST-1 on SY-SY5Y cells at 48h post-transfection transfected with highly puri-
fied miRNAs derived from Control, sCJD MM1 and sCJD VV2 cases (FC region). Statistical dif-
ferences are referred to controls. Statistical significance was set at p<0.05.
(TIF)
S1 Table. Excel file including the total RNA-sequence reads in each case (online).
(XLSX)
S2 Table. Excel file including the total number of reads mapping onto miRNAs. miRNAs
with at least 2 counts in a given sample (online).
(XLSX)
S3 Table. Excel file including regulated miRNAs detected in this study (online).
(XLSX)
S4 Table. Excel file displaying isomiRs detected in this study. Base mean > or equal to 10
(online).
(XLSX)
S5 Table. Table providing information on the functional enrichment analysis of miRNAs
identified based on small RNA-Seq in this study.
(TIF)
S6 Table. Top transcription factor binding sites enriched for promoter regions of target
downregulated (A) and upregulated (B) miRNAs in the FC of sCJD MM1 cases.
(TIF)
S7 Table. List of Taqman probes, miRCURY LNA primers and antibodies used in this
study.
(TIF)
S8 Table. Brain samples used in the present study. Diagnostic, sCJD subtype, brain region,
age, sex and the type of experiment for which each case was used (RNA-seq, miRNA qPCR,
mRNA qPCR and western blot) is indicated.
(TIF)
S9 Table. Demographics and biomarker profiling for the CSF samples analyzed in this
study. NA = Non-analyzed, + = positive according to sCJD cut-off, − = negative according to
sCJD cut-off. M = male, F = female.
(TIF)
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